Hosted on MSN1mon
Proof-of-concept study bioengineers therapeutics for improved cancer treatment
In a proof-of-concept study, the CMRI team has discovered two novel AAV capsids, known as AAV-T1 and AAV-T2, which can produce therapeutic CAR T cells using a five-fold lower dose of the vector.
Artificial Intelligence In 2025: Three Ways To Move From Proof Of Concept To Business Value Generation
Moving from an AI proof of concept to enterprise-wide business value generation is a massive hurdle that takes time and ...
The Bakersfield Californian12d
Mammoth Biosciences Announces New Results on NanoCas – the First Efficient Ultracompact Extrahepatic Gene Editor
Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...
CARGO Therapeutics, Inc. Announces Workforce Reduction and Strategic Shift
CARGO Therapeutics, Inc. (NASDAQ: CRGX) recently disclosed key updates regarding its strategic direction, workforce, and financial impacts. The company’s Board of Directors greenlit a decision to ...
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to ...
The Scientist20d
Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo
Artificial, Inc (“Artificial”), a technology company providing cloud-based solutions to streamline laboratory operations and accelerate life science discoveries, today announced proof of concept data ...